-
公开(公告)号：KR1020090084149A
公开(公告)日：2009-08-05
申请号：KR1020080010155
申请日：2008-01-31
Applicant: 한국과학기술연구원
IPC: A61K31/522 , A61K31/52 , A61P35/00
CPC classification number: A61K31/522
Abstract: A composition which contains caffeine, its analog, or its pharmaceutically allowable salt is provided to suppress infiltration, metastasis, and proliferation and prevent and/or treat brain cancer. A composition for preventing and treating brain cancer comprises caffeine, caffeine anaolog, or its pharmaceutically allowable salt as an active ingredient. The caffeine, caffeine analog or its pharmaceutically allowable salt has the content of 0.3-30 mM. The daily dose of the composition is 1-5 mg/kg and the composition is administered at one time or several times. The brain cancer is glioma, exothelioma, pituitary adenoma, schwannoma, craniopharyngioma or the congenital brain tumor. The composition selectively block the subtype 3 of activation of inositol-1,4,5-triphosphate receptoer(IP3R).
Abstract translation: 提供含有咖啡因，其类似物或其药学上可允许的盐的组合物以抑制浸润，转移和增殖，并预防和/或治疗脑癌。 用于预防和治疗脑癌的组合物包括咖啡因，咖啡因厌氧菌或其药学上可允许的盐作为活性成分。 咖啡因，咖啡因类似物或其药学上允许的盐的含量为0.3-30mM。 组合物的日剂量为1-5mg / kg，组合物一次或多次施用。 脑癌是神经胶质瘤，外皮瘤，垂体腺瘤，神经鞘瘤，颅咽管瘤或先天性脑瘤。 组合物选择性阻断肌醇-1,4,5-三磷酸盐受体（IP3R）的活化亚型3。
-
公开(公告)号：KR100892591B1
公开(公告)日：2009-04-08
申请号：KR1020070117886
申请日：2007-11-19
Applicant: 한국과학기술연구원
IPC: C07C229/58 , C07C229/52
CPC classification number: C07C229/58
Abstract: A chloride channel blocking agent containing anthranilic acid derivative is provided to show excellent validity and selectivity which result from excellent blocking activities of the anthranilic acid derivative. An anthranilic acid derivative is a compound having a structure represented by the formula I. In the formula I, R1 and R2 are independently selected from the group consisting of pentyl group, hexyl group, heptyl group, octyl group, decyl group, dodecyl group, tetradecyl group, hexadecyl group, cyclohexyl group, phenyl group, benzyl group, racemic-alphamethyl-benzyl group, chiral-alpha methyl-benzyl group, trifluoromethyl group, ethoxy group, butyloxy group, pentyloxy group, hexyloxy group, trifluoromethyloxy group and nitro group or two identical or different halogen atoms.
Abstract translation: 提供含有邻氨基苯甲酸衍生物的氯化物通道阻断剂，以显示由于邻氨基苯甲酸衍生物的优异的阻断活性而产生的优异的有效性和选择性。 邻氨基苯甲酸衍生物是具有由式I表示的结构的化合物。在式I中，R 1和R 2独立地选自戊基，己基，庚基，辛基，癸基，十二烷基， 十四烷基，十六烷基，环己基，苯基，苄基，外消旋 - 甲基 - 苄基，手性-α甲基 - 苄基，三氟甲基，乙氧基，丁氧基，戊氧基，己氧基，三氟甲氧基和硝基 或两个相同或不同的卤素原子。
-
公开(公告)号：KR100888379B1
公开(公告)日：2009-03-13
申请号：KR1020070053375
申请日：2007-05-31
Applicant: 한국과학기술연구원
Inventor： 이창준 , 우동호 , 트레이넬리스스테펜에프.
CPC classification number: G01N33/5058 , G01N2333/70571 , G01N2333/726
Abstract: 본 발명은 시냅스에서의 성상교세포와 뉴런 간의 새로운 커뮤니케이션 기작을 밝힌 것으로, 성상교세포에서 세포막에 위치하는 G-단백질 수용체를 활성화시킴으로써, 인접한 시냅스 후 뉴런 세포막의 글루타메이트 수용체를 활성화시켜서 세포내의 칼슘농도를 증가시키며, 탈분극을 유도하고 내향 전류를 증가시켜 뉴런에서의 신경 전달을 조절하는, 성상교세포-뉴런 간 신호화 기작에 관한 것이다.
-
公开(公告)号：KR101594421B1
公开(公告)日：2016-02-18
申请号：KR1020130091597
申请日：2013-08-01
Applicant: 한국과학기술연구원
Abstract: 본발병은망막에존재하는 ON 또는 OFF 이극세포에선택적으로광유전자를발현시키기위한방법으로, 구체적으로는 ON 이극세포에특이적으로발현하는프로모터, 제1 표적유전자및 Cre 유전자를포함하는제1 벡터및 ON/OFF 이극세포에발현하는프로모터, 제2 표적유전자및 loxP 서열을포함하는제2 벡터를포함하는이극세포에서선택적유전자발현용키트및 이를이극세포에도입하여이극세포에서유전자를선택적으로발현시키는방법에관한것이다. 일구체예에서개시된바업을이용할경우광수용체가없을경우에도이극세포에서빛을감지할수 있으며, 이러한경우광수용체가사멸하는안질환을갖는환자에게효과적인치료법을제공할수 있다.
-
公开(公告)号：KR1020130020949A
公开(公告)日：2013-03-04
申请号：KR1020120089402
申请日：2012-08-16
Applicant: 한국과학기술연구원
Abstract: PURPOSE: A pharmaceutical composition for preventing or treating neurodegenerative diseases, and a method for screening the same are provided to effectively screen a material which prevents or treats neurodegenerative diseases. CONSTITUTION: A method for screening a pharmaceutical composition for preventing or treating neurodegenerative diseases comprises: a step of contacting a sample to be analyzed with a reactive astrocyte; a step of measuring the reduction of GABA concentration in the reactive astrocyte or GABA release from the reactive astrocyte; and a step of determining a material which prevents or treats neurodegenerative diseases when the sample reduces the GABA concentration or GABA release.
Abstract translation: 目的：提供用于预防或治疗神经变性疾病的药物组合物及其筛选方法，以有效筛选预防或治疗神经变性疾病的材料。 构成：用于筛选用于预防或治疗神经变性疾病的药物组合物的方法包括：将待分析样品与活性星形胶质细胞接触的步骤; 测量来自反应性星形胶质细胞的反应性星形胶质细胞或GABA释放中GABA浓度降低的步骤; 以及当样品降低GABA浓度或GABA释放时，确定预防或治疗神经变性疾病的材料的步骤。
-
Patent Agency Ranking
-
公开(公告)号：KR101853058B1
公开(公告)日：2018-04-27
申请号：KR1020160110775
申请日：2016-08-30
Applicant: 한국과학기술연구원
IPC: C12N5/00 , C12N5/0793 , C12N5/079 , C12M1/00 , C12M1/42
Abstract: 본명세서는세포배양물질을정렬하기위한장치및 방법에관한것이다. 구체적으로본 명세서는 (1) 탄성기판을압축하는단계; (2) 압축된탄성기판에세포배양용물질을로딩하는단계; 및 (3) 탄성기판을원상회복시키는단계를포함하는세포배양용물질을단일한방향으로정렬하는방법을제공한다. 또한, 본명세서는세포배양용물질이로딩되는탄성기판; 및상기탄성기판의폭을압축시키는압축모듈을포함하는세포배양용물질의정렬장치를제공한다.
-
公开(公告)号：KR101850307B1
公开(公告)日：2018-04-20
申请号：KR1020160025885
申请日：2016-03-03
Applicant: 한국과학기술연구원
CPC classification number: C12N5/0693 , B29C43/02 , B29C43/18 , B29C43/36 , B29C2043/185 , B29K2995/0046 , C08J7/047 , C08J2383/04 , C08J2465/00 , C12M21/08 , C12M25/14 , C12N5/0068 , C12N2513/00 , C12N2533/30 , C12N2533/54 , C12N2535/00
Abstract: 본명세서는채널결합형스캐폴드를제조하기위한장치및 방법에관한것이다. 구체적으로본 명세서는 (1) 기판표면에홈을포함하는제1탄성기판을압축하여홈을닫는단계; (2) 닫힌홈 위에스캐폴드조성물을로딩하는단계; 및 (3) 탄성기판을원상회복시키는단계를포함하는채널결합형스캐폴드의제조방법을제공한다. 또한, 본발명은일측면에있어서기판표면에홈을포함하고그 위에스캐폴드조성물이로딩되는제1탄성기판; 및탄성기판의홈을닫기위해그 폭을압축시키는압축모듈을포함하는채널결합형스캐폴드의제조장치를제공한다.
-
公开(公告)号：KR101746060B1
公开(公告)日：2017-06-12
申请号：KR1020150132281
申请日：2015-09-18
Applicant: 한국과학기술연구원
IPC: C07C309/14 , C07C309/15 , A61K31/165 , A61K31/18
Abstract: 본발명은알파-아미노아미드유도체화합물및 이를포함하는항비만치료용약학조성물에관한것이다. 본발명의여러구현예에따르면상기알파-아미노아미드유도체는마오비와비공유결합을통해가역적으로마오비를억제할수 있으며, 종래의마오비저해제보다뛰어난안정성및 효능을가지므로마오비제어제로유용하게이용할수 있다. 또한선택적으로에너지소비를유도하는 POMC 신경세포에작용하여비만치료효과를나타낸다.
-
公开(公告)号：KR1020140058480A
公开(公告)日：2014-05-14
申请号：KR1020140047606
申请日：2014-04-21
Applicant: 한국과학기술연구원
IPC: A61K31/4741 , A61K31/4743 , A61K31/4745 , A61K31/4738 , G01N33/53 , G01N33/15 , G01N33/68 , A61P25/28 , A61P25/00
CPC classification number: A61K31/44 , A61K31/437 , A61K31/55
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, and a screening method thereof. According to an embodiment of the present invention, by applying the screening method which screens candidate substances for preventing or treating neurodegenerative diseases, a substance for preventing or treating neurodegenerative diseases can be effectively screened. The pharmaceutical composition for preventing or treating neurodegenerative diseases obtained by the screening method can effectively prevents or treats various neurodegenerative diseases.
Abstract translation: 本发明涉及用于预防或治疗神经变性疾病的药物组合物及其筛选方法。 根据本发明的一个实施方案，通过应用筛选候选物质的预防或治疗神经变性疾病的筛选方法，可以有效地筛选用于预防或治疗神经变性疾病的物质。 用于预防或治疗通过筛选方法获得的神经变性疾病的药物组合物可以有效地预防或治疗各种神经变性疾病。
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.029 seconds)
